DRI Healthcare Trust
DRI Healthcare Trust (DHT-U.TO) Financial Performance & Income Statement Overview
Explore the financials of DRI Healthcare Trust (DHT-U.TO), including yearly and quarterly data on income, cash flow, and balance sheets.
DRI Healthcare Trust (DHT-U.TO) Income Statement & Financial Overview
Review DRI Healthcare Trust DHT-U.TO income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $39.93M | $47.43M | $36.75M | $29.32M |
| Cost of Revenue | $0.00 | $17.25M | $27.92M | -$12.29M |
| Gross Profit | $39.93M | $30.17M | $13.97M | $41.60M |
| Gross Profit Ratio | $1.00 | $0.64 | $0.38 | $1.42 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.95M | $4.20M | $6.05M | $2.51M |
| Operating Expenses | $31.56M | $7.35M | $31.71M | $31.45M |
| Total Costs & Expenses | $31.56M | $48.82M | $40.10M | $30.14M |
| Interest Income | $298000.00 | $382000.00 | $774000.00 | $577000.00 |
| Interest Expense | $9.61M | $9.49M | $8.55M | $8.64M |
| Depreciation & Amortization | $24.75M | $25.31M | $26.10M | $25.64M |
| EBITDA | $32.50M | -$735040.00 | $33.95M | $31.55M |
| EBITDA Ratio | $0.81 | -$0.02 | $0.92 | $1.08 |
| Operating Income | -$1.75M | $7.001M | $0.00 | -$20.60M |
| Operating Income Ratio | -$0.04 | $0.15 | $0.00 | -$0.70 |
| Other Income/Expenses (Net) | $0.00 | $0.00 | -$1.69M | $18.47M |
| Income Before Tax | -$1.75M | $7.001M | -$1.69M | -$2.13M |
| Income Before Tax Ratio | -$0.04 | $0.15 | -$0.05 | -$0.07 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.75M | $7.001M | -$1.69M | -$2.13M |
| Net Income Ratio | -$0.04 | $0.15 | -$0.05 | -$0.07 |
| EPS | -$0.03 | $0.12 | -$0.03 | -$0.04 |
| Diluted EPS | -$0.03 | $0.12 | -$0.03 | -$0.04 |
| Weighted Avg Shares Outstanding | $56.31M | $56.32M | $56.29M | $53.33M |
| Weighted Avg Shares Outstanding (Diluted) | $56.31M | $56.32M | $56.29M | $56.43M |
Over the last four quarters, DRI Healthcare Trust achieved steady financial progress, growing revenue from $29.32M in Q2 2024 to $39.93M in Q1 2025. Gross profit stayed firm with margins at 100% in Q1 2025 versus 142% in Q2 2024. Operating income totaled -$1.75M in Q1 2025, maintaining a -4% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $32.50M. Net income dropped to -$1.75M, with EPS at -$0.03. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan